Verdad Advisers’s Axsome Therapeutics AXSM Stock Holding History

Verdad Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,971	Closed	-$1.01M	–	219
2026 Q1	$1.01M	Buy	+5,971	New	+$1.03M	1.14%	21

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Verdad Advisers's AXSM Position: Q2 2026 in Review

Verdad Advisers sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 5,971 shares — an estimated $1.01M sold.

Verdad Advisers first reported a position in AXSM in Q1 2026 and held it in 1 quarter. The position peaked at $1.01M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Verdad Advisers reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
Verdad Advisers sold 5,971 Axsome Therapeutics shares in Q2 2026, an estimated $1.01M.
Verdad Advisers first reported a position in Axsome Therapeutics in Q1 2026 and held it in 1 quarter.
Verdad Advisers's Axsome Therapeutics position peaked at $1.01M in Q1 2026.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.